<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Trial</th>
<th>Efficacy</th>
<th>Variants</th>
<th>Specifics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>mRNA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer/BioNTech (BNT162b2)</td>
<td>Phase 3, 2 doses (45,000)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderna (mRNA-1273)</td>
<td>Phase 3, 2 doses (30,000)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Viral Vector</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Johnson &amp; Johnson (Ad26.COV2.S)</td>
<td>Phase 3, 2 doses (44,000)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Protein Subunit</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxford/AstraZeneca (AZD1222)</td>
<td>Phase 3, 2 doses (30,000)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>VLP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Merck (V591)</td>
<td>Phase 3, 2 doses (30,000)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Vaccine**

- **mRNA**
- **Viral Vector**
- **Protein Subunit**
- **VLP**

**Trial**

- Phase 3, 2 doses
- Phase 3, 2 doses
- Phase 3, 2 doses
- Phase 3, 2 doses

**Efficacy**

- Pfizer/BioNTech: 95% (5 doses, 0.5 mL), 89.3% (95.6% if only measuring strain)
- Moderna: 94% (5 doses, 0.3 mL), 95% (5 doses, 0.3 mL)
- Johnson & Johnson: 76% (2 doses, 0.5 mL), 80% (2 doses, 0.5 mL)
- Oxford/AstraZeneca: 80% (2 doses, 0.5 mL), 89% (2 doses, 0.5 mL)
- Merck: 89% (2 doses, 0.5 mL), 90.6% (2 doses, 0.5 mL)
- Novavax: 90% (2 doses, 0.5 mL), 89.5% (2 doses, 0.5 mL)
- Sanofi Pasteur/GSK (SCB-2019): Not quantified
- Medicago/GSK (CoVLP): Not quantified

**Variants**

- Pfizer/BioNTech: MDV (5 doses, 0.5 mL), MDV (5 doses, 0.3 mL)
- Moderna: MDV (10 doses, 0.5 mL)
- Johnson & Johnson: MDV (5 doses, 0.3 mL)
- Oxford/AstraZeneca: MDV (10 doses, 0.3 mL)
- Novavax: MDV (10 doses, 0.3 mL)
- Sanofi Pasteur/GSK (SCB-2019): Not quantified
- Medicago/GSK (CoVLP): Not quantified

**Specifics**

- **Stability after opening**
  - Pfizer/BioNTech: Stable up to 6 hours after dilution.
  - Moderna: Stable up to 6 hours after puncture.
  - Johnson & Johnson: Stable up to 6 hours after puncture.
  - Oxford/AstraZeneca: Stable up to 6 hours after puncture.
  - Novavax: Stable up to 6 hours after puncture.
  - Sanofi Pasteur/GSK (SCB-2019): Stable up to 6 hours after puncture.
  - Medicago/GSK (CoVLP): Stable up to 6 hours after puncture.
- **Can overlap be used as extra doses?**
  - Pfizer/BioNTech: Yes
  - Moderna: No
  - Johnson & Johnson: No
  - Oxford/AstraZeneca: No
  - Novavax: No
  - Sanofi Pasteur/GSK (SCB-2019): No
  - Medicago/GSK (CoVLP): No

---

**Disclaimer**

The information contained in this vaccine informational sheet is emerging and rapidly evolving because of ongoing research and events and is subject to professional judgment and interpretation. The precautionary due to the uniqueness of the needs of individual patients. ASHP provides this information to help practitioners better understand the current status of COVID-19 vaccine tracking. ASHP has made reasonable efforts to ensure the accuracy and appropriateness of the information contained in this vaccine information sheet and has taken no responsibility or liability for the results or consequences of its use.

**References**

5. https://clinicaltrials.gov/

**ASHP Statement**

ASHP will continue to advocate on behalf of our members and support COVID-19 vaccine planning efforts, a number of resources, including ASHP’s Principles for COVID-19 Vaccine Distribution, Allocation, and Immunization, are available on our COVID-19 Vaccine page.

https://www.ashp.org/Covid-19